0001104659-22-029462.txt : 20220302
0001104659-22-029462.hdr.sgml : 20220302
20220302190041
ACCESSION NUMBER: 0001104659-22-029462
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20220228
FILED AS OF DATE: 20220302
DATE AS OF CHANGE: 20220302
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Harris Matthew Scott
CENTRAL INDEX KEY: 0001787762
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-32587
FILM NUMBER: 22705831
MAIL ADDRESS:
STREET 1: C/O ALTIMMUNE, INC.
STREET 2: 910 CLOPPER ROAD, SUITE 201S
CITY: GAITHERSBURG
STATE: MD
ZIP: 20878
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Altimmune, Inc.
CENTRAL INDEX KEY: 0001326190
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 202726770
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 910 CLOPPER ROAD
STREET 2: SUITE 201S
CITY: GAITHERSBURG
STATE: MD
ZIP: 20878
BUSINESS PHONE: 2406541450
MAIL ADDRESS:
STREET 1: 910 CLOPPER ROAD
STREET 2: SUITE 201S
CITY: GAITHERSBURG
STATE: MD
ZIP: 20878
FORMER COMPANY:
FORMER CONFORMED NAME: PHARMATHENE, INC
DATE OF NAME CHANGE: 20071016
FORMER COMPANY:
FORMER CONFORMED NAME: HEALTHCARE ACQUISITION CORP
DATE OF NAME CHANGE: 20050505
4
1
tm228203-1_4seq1.xml
OWNERSHIP DOCUMENT
X0306
4
2022-02-28
0
0001326190
Altimmune, Inc.
ALT
0001787762
Harris Matthew Scott
C/O ALTIMMUNE, INC., 910 CLOPPER ROAD,
SUITE 201S
GAITHERSBURG,
MD
20878
0
1
0
0
Chief Medical Officer
Common Stock, par value $0.0001
2022-02-28
4
M
0
30000
1.9213
A
41545
D
Common Stock, par value $0.0001
2022-02-28
4
S
0
30000
7.52
D
11545
D
Stock Options (option to buy)
1.9213
2022-02-28
4
M
0
30000
0.00
D
2030-01-02
Common Stock, par value $0.0001
30000
31400
D
The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $7.30 to $7.70, inclusive. The reporting person undertakes to provide to Altimmune, Inc., any security holder of Altimmune, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote.
Twenty-five percent of the shares underlying the option became vested and exercisable on January 2, 2021 and the remaining 75% of the shares underlying the option become vested and exercisable in substantially equal monthly installments over the 36 months following January 2, 2021, subject to the reporting person's continued service through the applicable vesting date.
/s/ Kent Tapper, as Attorney-in-Fact
2022-03-02